News & Events
BD Submits 510(k) Application to FDA for Alternate Site Testing
|
Contact: Patricia A. Spinella Investor Relations (201) 847-5453 Email: patricia_spinella@bd.com Colleen T. White Corporate Communications (201) 847-5369 Email: colleen_white@bd.com Franklin Lakes, NJ (June 10, 2004) -- BD (Becton, Dickinson and Company) (NYSE: BDX) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a 510(k) application for clearance to use the BD Logic™ and Paradigm Link™ blood glucose meters for alternate site testing (off-finger).
BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. For the fiscal year ended September 30, 2003, BD reported total revenues of $4.528 billion.
|